Funding for this research was provided by:
innovative medicines initiative (115300, 777394)
medical research council (MR/K021389/1, MR/T003057/1)
Received: 2 July 2021
Accepted: 3 November 2021
First Online: 15 December 2021
: The study was approved by the local ethical committees of participating centres, and written informed consent was obtained from all participants or their legal guardians (for participants < 18 years).
: Not applicable.
: FS consults for Roche, Janssen and BlackThorn Therapeutics. SB discloses that he has in the last 3 years acted as an author, consultant or lecturer for Medice and Roche. He receives royalties for text books and diagnostic tools from Hogrefe, Kohlhammer and UTB. JB has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.